Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020095901 - METHOD FOR PRODUCING BLOOD PREPARATION AND BLOOD PREPARATION

Publication Number WO/2020/095901
Publication Date 14.05.2020
International Application No. PCT/JP2019/043303
International Filing Date 05.11.2019
IPC
A61K 35/19 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
19Platelets; Megacaryocytes
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 35/18 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
18Erythrocytes
A61K 47/22 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 7/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Applicants
  • テルモ株式会社 TERUMO KABUSHIKI KAISHA [JP]/[JP]
Inventors
  • 武田 典彦 TAKEDA, Norihiko
Agents
  • 八田国際特許業務法人 HATTA & ASSOCIATES
Priority Data
2018-20937407.11.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) METHOD FOR PRODUCING BLOOD PREPARATION AND BLOOD PREPARATION
(FR) PROCÉDÉ DE PRODUCTION DE PRÉPARATION DE SANG ET PRÉPARATION DE SANG
(JA) 血液製剤の製造方法、および血液製剤
Abstract
(EN)
[Problem] To provide a means for successfully deactivating the pathogens in a blood sample containing both erythrocytes and platelets while sufficiently reducing the hemolysis rate of a final erythrocyte preparation. [Solution] When a blood preparation containing erythrocytes and platelets is produced, a blood sample containing erythrocytes and platelets is irradiated with UV rays in the presence of a hemolysis inhibitor and a surfactant having an HLB value of 13 or greater and a molecular structure in which at least 20 oxyethylene groups are included in the hydrophilic moiety.
(FR)
La présente invention aborde le problème de la réalisation un moyen permettant de réussir la désactivation des pathogènes dans un échantillon de sang contenant à la fois des érythrocytes et des plaquettes tout en réduisant suffisamment le taux d'hémolyse d'une préparation finale d'érythrocytes. Avec la solution selon l'invention, lorsqu'une préparation de sang contenant des érythrocytes et des plaquettes est produite, un échantillon de sang contenant des érythrocytes et des plaquettes est irradié avec des rayons UV en présence d'un inhibiteur d'hémolyse et un tensioactif ayant une valeur HLB égale ou supérieure à 13 et une structure moléculaire dans laquelle au moins 20 groupes oxyéthylène sont inclus dans la fraction hydrophile.
(JA)
【課題】最終的に得られる赤血球製剤の溶血率を十分に低下させつつ、赤血球と血小板とをともに含有する血液試料における病原体の不活化を達成しうる手段を提供する。 【解決手段】赤血球と血小板とを含有する血液製剤を製造する際に、溶血防止剤と、HLB値が13以上で分子構造中の親水部のオキシエチレン基数が20以上である界面活性剤との存在下で、赤血球と血小板とを含有する血液試料に対して紫外線を照射する。
Latest bibliographic data on file with the International Bureau